The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma

Abstract

BACKGROUND AND PURPOSEAsthma is characterized by chronic lung inflammation and airway hyperresponsiveness. Despite recent advances in understanding of its pathophysiology, asthma remains a major public health problem, and new therapeutic strategies are urgently needed. In this context, we sought to ascertain whether treatment with the TK inhibitor dasatinib might repair inflammatory and remodelling processes, thus improving lung function, in a murine model of asthma. EXPERIMENTAL APPROACHAnimals were sensitized and subsequently challenged, with ovalbumin (OVA) or saline. Twenty-four hours after the last challenge, animals were treated with dasatinib, dexamethasone, or saline, every 12 h for 7 consecutive days. Twenty-four hours after the last treatment, the animals were killed, and data were collected. Lung structure and remodelling were evaluated by morphometric analysis, immunohistochemistry, and transmission electron microscopy of lung sections. Inflammation was assessed by cytometric analysis and ELISA, and lung function was evaluated by invasive whole-body plethysmography. KEY RESULTSIn OVA mice, dasatinib, and dexamethasone led to significant reductions in airway hyperresponsiveness. Dasatinib was also able to attenuate alveolar collapse, contraction index, and collagen fibre deposition, as well as increasing elastic fibre content, in OVA mice. Concerning the inflammatory process, dasatinib reduced inflammatory cell influx to the airway and lung-draining mediastinal lymph nodes, without inducing the thymic atrophy promoted by dexamethasone. CONCLUSIONS AND IMPLICATIONSIn this model of allergic asthma, dasatinib effectively blunted the inflammatory and remodelling processes in asthmatic lungs, enhancing airway repair and thus improving lung mechanics. AbbreviationsBALF, bronchoalveolar lavage fluid; OVA, ovalbumin; Th2, T helper 2 lymphocytes

Eicosapentaenoic Acid Enhances the Effects of Mesenchymal Stromal Cell Therapy in Experimental Allergic Asthma

“…The left lung was fixed with Carnoy’s solution and paraffin-embedded ( 28 ). Sections (4-µm thick) were cut and stained with hematoxylin-eosin for morphometric analysis of lung structure ( 27 , 29 ). Lung morphometry analysis was performed using an integrating eyepiece with a coherent system consisting of a grid with 100 points and 50 lines of known length coupled to a conventional light microscope (Olympus BX51, Olympus Latin America-Inc., Brazil).…”

Serum from Asthmatic Mice Potentiates the Therapeutic Effects of Mesenchymal Stromal Cells in Experimental Allergic Asthma

“…Briefly, an integrating eyepiece with a coherent system consisting of a grid with 100 points and 50 lines of known length was coupled to a conventional light microscope (Olympus BX51, Olympus Latin America‐Inc., Brazil). The number of mononuclear (MN) and polymorphonuclear (PMN) cells in each section was determined by the point‐counting technique across 10 random, noncoincident fields of view per mouse.…”

Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma

“…Dexamethasone therapy also reduced the percentage of CD4 − CD8 + cells in the thymus, as reported elsewhere. 35 Multiple doses of MSCs resulted in inhibition of CD4 + T-cell maturation, but had less effect on CD8 + T-cell development.…”